Medical technology · Market access & commercial strategy
Proven medical technology, brought to new markets.
Cencor Technologies is a London-based market-access and commercial strategy firm for medical-device manufacturers. We turn regulatory clearance into clinical adoption and commercial growth across Europe, the Gulf, and international healthcare markets.
What we do
Market access, end to end.
Most manufacturers buy regulatory, clinical and commercial support from three different suppliers. We bring them together, so the route from clearance to revenue is one coherent plan rather than three disconnected ones.
Commercial strategy & market entry
Territory assessment, pricing and channel strategy, and a launch plan built around how each market actually buys.
Regulatory & device registration
CE-based technical files and in-country registration — MOHAP, SFDA, CND/RDM, ALIMS, AEMPS — through licensed local representatives.
KOL & clinical engagement
Key opinion leader relationships, clinical validation studies, and the published evidence that drives institutional adoption.
Distribution network management
Identifying, appointing and managing national distributors, with the controls and reporting to keep a portfolio coherent.
Market access & reimbursement
Health-technology assessment, payer engagement and formulary inclusion to move from first sales to sustained volume.
Business development & partnerships
Structuring distribution and agency agreements that protect manufacturers and align incentives across the chain.
Focus area · exclusive commercial partner
Re5 T-PEMF neurotechnology.
Cencor is the exclusive commercial partner for Re5 — the only EU MDR–certified home neurostimulation system with sham-controlled efficacy in treatment-resistant depression, including in patients who have not responded to ECT, and a growing evidence base in Parkinson’s disease.
Re5 delivers sub-threshold TMS in the form of T-PEMF — transcranial pulsed electromagnetic fields. It is electrode-free and imperceptible, given in 30-minute daily sessions at home. As exclusive commercial partner and export agency, Cencor leads its commercial development, device registration and clinical engagement market by market.
Re5® is a medical device of Re5 ApS (Denmark). Information for healthcare professionals and institutional decision-makers; approved indications and availability vary by market and are subject to local regulatory authorisation.
How it works
Sub-threshold TMS, explained.
Sub-threshold TMS works below the intensity at which neurons fire — far lower than conventional (suprathreshold) TMS. Because the stimulation is imperceptible, it avoids the scalp pain, muscle contraction and seizure risk of conventional TMS, which is what makes safe home use possible — and what strengthens the integrity of sham-controlled trials. T-PEMF is the specific protocol Re5 delivers: a seven-coil, non-focal headset applying 50 Hz pulses across the cortex, developed at Danish research institutions and in routine use in Danish public psychiatry.
Apply
A seven-coil electromagnetic headset is worn over the scalp — no electrodes, no scalp preparation. 30-minute sessions, daily, at home.
Induce
Pulsed electromagnetic fields (50 Hz, 3 ms pulses) induce weak electric fields in brain tissue — sub-threshold and imperceptible.
Activate
Those fields activate intracellular processes, prompting release of neurotransmitters and growth factors that support neuroplasticity.
Accelerate
Activated cells signal neighbouring cells, propagating the biochemical response across neural networks.
Regenerate
Over roughly five to eight weeks, measurable gains in neural connectivity, blood flow and function emerge.
Clinical evidence
Backed by peer-reviewed science.
Re5’s clinical claims rest on sham-controlled randomised trials, dose-response and independent studies, and real-world outcomes — documented in its EU MDR Clinical Evaluation Report.
Treatment-resistant depression
Efficacy comparable to clinic TMS — at home
Parkinson’s disease
Mobility, function and a biomarker signal
Selected references: Martiny 2010; Straasø 2014; Bech 2015; Larsen 2020; Morberg 2018; Jensen 2021. Figures are drawn from peer-reviewed studies and Re5’s Clinical Evaluation Report (REP-02-402), available to qualified partners and institutions on request.
Where we operate
Europe, the Gulf, and beyond.
We build market access where we have real channels and clinical relationships — and assess new territories on request, structuring the regulatory and distribution route before committing to launch.
Active markets
Development markets
Reach
How we work
Three steps from clearance to growth.
Assess
Territory, regulatory pathway, competitive landscape, and the realistic commercial case — before any commitment.
Register & establish
Licensed local authorised representative, device registration, and the distribution structure for the market.
Launch & scale
Clinical and KOL engagement, payer and reimbursement work, and ongoing network management toward sustained volume.
About
A specialist partner, not a generalist agency.
Cencor Technologies Ltd is a medical-technology commercial strategy, market access and business development company based in London, with established operational sales networks across European and international healthcare markets.
We work as an extension of the manufacturers we represent, combining regulatory, clinical and commercial expertise that is usually split across separate suppliers — so principals deal with one accountable partner from first assessment to sustained sales.
- Headquarters
- 1 Charterhouse Mews, London, England, EC1M 6BB
- Registration
- Cencor Technologies Ltd · Company No. 11057742
- Sector
- Medical devices & neurotechnology market access
- Reach
- European Union · GCC · selected international markets
Get in touch
Tell us about your market.
Whether you manufacture a device that needs a route into Europe or the Gulf, or you are a distributor seeking proven technology to represent, we would like to hear from you.